This pharmaceutical-grade protected ribofuranose is designated for manufacturing routes that lead to APIs for tablet, capsule, granule, and injectable dosage forms, both oral and parenteral. For manufacturers of antiviral, antiretroviral, and antineoplastic nucleoside APIs, 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose is a crystalline C1-activated ribofuranose building block rather than a directly compressible active ingredient. The compound is registered under CAS 6974-32-9, molecular formula C₂₈H₂₄O₉, and molecular weight 504.49 g/mol. The three benzoyl protecting groups at O-2, O-3, and O-5 and the single β-oriented anomeric acetate provide regio- and stereochemical control during Vorbrüggen glycosylation. No international pharmacopoeial model number applies to this protected intermediate; the manufacturer’s internal grade code is referenced on the batch-specific certificate of analysis as either oral or injectable starting-material grade depending on endotoxin and bioburden controls. The material is released with residual solvent limits aligned to ICH Q3C and elemental impurity controls aligned to ICH Q3D. It is not directly formulated into tablets, capsules, granules, or injections; it is the protected starting material used to prepare nucleoside APIs that are subsequently formulated into those dosage forms.

Why Is the β-Anomeric 1-O-Acetyl Configuration Maintained During Vorbrüggen Glycosylation?

The β anomer is specified because the desired nucleoside APIs in the antiviral and antineoplastic classes require β-configuration at the anomeric centre. Under Lewis acid-catalysed coupling with trimethylsilyl triflate or tin tetrachloride in dichloromethane or acetonitrile, the 1-O-acetyl group is activated without removing the O-benzoyl groups. Published coupling protocols for acylated ribofuranose derivatives report temperature control at 0 °C to 25 °C as a critical processing window; above 50 °C, α-anomer formation and debenzoylation by-products can increase. In glass-lined pilot reactors with jacket temperature control calibrated to ±2 °C, the exothermic coupling is controlled by addition of the silylated nucleobase over 30–60 min. More rapid addition is associated with local temperature excursions and reduced β/α selectivity. Because only the anomeric carbon is activated, the competing O-glycosylation and non-anomeric N-glycosylation pathways observed with unprotected D-ribose are suppressed.

Chromatographic release of the β-anomer is performed by reversed-phase HPLC with a C18 column and acetonitrile/water mobile phase. The α-anomer, generated during storage or forced degradation, is resolved as a separate peak. For stereochemically critical β-nucleoside synthesis, the α-anomer is controlled at ≤0.20% area; the total impurity limit remains ≤1.00% area.

Release testing for the pharmaceutical-grade material is performed on every batch. The HPLC procedure uses UV detection at 254 nm, where the benzoyl chromophores provide a linear response without derivatization. Headspace gas chromatography on a 30 m × 0.32 mm DB-624 column with flame ionization detection and split injection at 140 °C separates methanol, acetone, dichloromethane, ethyl acetate, and toluene from the sample matrix. Inductively coupled plasma mass spectrometry after closed-vessel microwave digestion is used for elemental impurities, with method detection limits below 0.1 ppm for lead, cadmium, arsenic, and mercury. The specification in Table 1 is representative for oral solid dosage starting material; injectable-derived APIs may require additional endotoxin and particulate controls.

Pharmaceutical utility depends on anomeric ratio as well as overall chromatographic purity. Normal-phase thin-layer chromatography on silica gel 60 F254 plates with hexane/ethyl acetate 7:3 is used as an in-process check; visualisation by UV at 254 nm detects the benzoyl-bearing components. The α-anomer is the most relevant process-related impurity because it can propagate to an undesired α-nucleoside in downstream coupling, and its control is more stringent than the general single-impurity limit when the final API requires high stereochemical purity.

Residual Benzoyl Chloride, Acyl Migration, and Drying Cycle Controls

Process-related impurities in this protected ribofuranose include benzoic acid, positional benzoyl isomers, and the des-acetyl 2,3,5-tri-O-benzoyl-β-D-ribofuranose. Residual benzoyl chloride is hydrolysed to benzoic acid during aqueous workup; benzoic acid is controlled at ≤0.10% area by HPLC. Acyl migration can occur if the crude material is held at pH <6 or >8 during workup or if the drying temperature exceeds 45 °C for prolonged periods. In agitated nutsche filter/dryers with vacuum levels of -0.08 MPa and jacket temperature 35–40 °C, residual methylene chloride is typically reduced below the ICH Q3C limit of 600 ppm within 12 h; batches with a mean crystal size above 150 µm may require extended cycles because solvent inclusion is released more slowly. Each lot is assayed by headspace GC to confirm the drying end point rather than relying only on time. The use of a nitrogen-purged vacuum oven is preferred for storage after drying because the product is hygroscopic at relative humidity above 60%.

Because the protecting groups are ester-linked, the product is incompatible with strong aqueous alkali, primary amines, and prolonged contact with methanolic ammonia. Storage in tightly closed containers under inert gas at 2–8 °C stabilizes anomeric purity; storage at ambient temperature 25 °C is acceptable for 12 months only if the container remains sealed and protected from light. If the water content exceeds 0.50%, pre-drying in a vacuum oven at 35–40 °C for 2–4 h is recommended before water-sensitive coupling.

For tablet, capsule, and granule manufacture, the protected intermediate is not subjected to direct compression, encapsulation, or high-shear granulation. The derived nucleoside API is the material that enters the dosage-form process. The relevant upstream controls are residual solvent selection, elemental impurity limits calculated from the final daily dose, and the absence of Class 1 solvents. Particle-size distribution of the protected intermediate does not control tablet hardness or capsule fill weight; those attributes are controlled on the final API.

When Injectable-Grade Starting Material Is Required for Nucleoside API Synthesis

If the final nucleoside API is intended for injectable dosage forms, the starting material specification is expanded to include bioburden and bacterial endotoxin control. The intermediate is not sterile and is not directly injectable. Endotoxin limits are derived from the final injectable dose and the validated reduction across downstream steps; a starting-material control of ≤0.25 EU/mg may be acceptable only when the downstream process provides at least 10-fold endotoxin reduction. Without that validation, tighter limits are applied. The final API must meet USP 85 for bacterial endotoxins, USP 788 for particulate matter in injections, and ICH Q3D injectable elemental impurity limits. Water content and residual solvents become more critical because later lyophilization or sterile filtration does not reliably remove residual solvents. Published data for this specific intermediate in injectable final dosage forms is limited to process-specific dossiers; therefore, each manufacturing route is validated rather than relying on a universal specification.

Comparative Performance Against Unprotected Ribose and Peracetylated Ribofuranose

Direct comparison with alternative ribose donors shows three relevant distinctions. The benzoylated acetate is crystalline and anomerically uniform, whereas unprotected D-ribose exists as an equilibrating α/β mixture in aqueous solution and contains four reactive hydroxyl groups that generate complex glycosylation product distributions. The peracetylated derivative, 1,2,3,5-tetra-O-acetyl-β-D-ribofuranose, provides a lower molecular weight and easier deprotection, but it lacks the benzoyl UV chromophore and offers less steric protection during coupling.